sur Heidelberg Pharma AG (ETR:HPHA)
Heidelberg Pharma Appoints New CEO Amidst Executive Changes
Ladenburg, Germany, 24 November 2025 – Heidelberg Pharma AG, a clinical-stage biotech firm known for its innovative Antibody Drug Conjugates (ADCs), announced significant changes to its Executive Management Board. Dr. Dongzhou Jeffery Liu has been appointed as the new Chairman and Chief Executive Officer, replacing Professor Andreas Pahl. This decision by the Supervisory Board is effective immediately.
Dr. Liu, previously a member of Heidelberg Pharma's Supervisory Board, will permanently assume his new role on 24 December 2025. He brings over 25 years of pharmaceutical industry experience, having held positions at major companies including GlaxoSmithKline and Pfizer.
Dr. Liu's appointment aligns with Heidelberg Pharma's commitment to advancing oncology treatments, specifically through their unique Amanitin-based ADC technologies for cancer therapy. The company's strategic focus remains on developing novel treatments for multiple cancer types.
R. H.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Heidelberg Pharma AG